Apixaban — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial Fibrillation (Stroke Prevention)

• Warfarin Sodium
• Amiodarone
• Dabigatran
• Digoxin
• Metoprolol
• Rivaroxaban
• Warfarin

Also listed for Deep Vein Thrombosis

• Enoxaparin

Other medications in Heart & Cardiovascular

• Atenolol
• Atorvastatin
• Azilsartan
• Bempedoic Acid
• Benazepril
• Bisoprolol
• Bosentan
• Bumetanide

About Apixaban

Apixaban is a crucial anticoagulant medication often prescribed to prevent dangerous blood clots. For those managing conditions like atrial fibrillation or DVT, access to this vital drug is paramount. TheDrugClub understands the financial burden of prescriptions and is dedicated to making essential medications like apixaban affordable, offering significant savings to our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Apixaban is approved for (FDA label)

ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.

Source: Read the full FDA label on DailyMed. Label effective date: April 24, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Apixaban (FDA label)

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.5) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of ELIQUIS and neuraxial procedures is not known [see Warnings and Precautions (5.3) ] Monitor patients frequently for signs and symptoms of neurological impairment.

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Apixaban (FDA label)

• 0.5 mg, pink, round, film-coated tablets for oral suspension packaged in packets. 1-count (0.5 mg), 3-count (1.5 mg), and 4-count (2 mg). • 2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side and “2½” on the other side. • 5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side and “5” on the other side. • 0.15 mg, white to pale yellow powder for oral suspension, in a yellow opaque capsule marked “898”. • Tablets: 2.5 mg and 5 mg (3) • Tablet For Oral Suspension: 0.5 mg (3) • For Oral Suspension: 0.15 mg in a yellow opaque capsule (3)

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Apixaban (FDA label)

The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information. • Increased Risk of Thrombotic Events After Premature Discontinuation [see Warnings and Precautions (5.1) ] • Bleeding [see Warnings and Precautions (5.2) ] • Spinal/Epidural Anesthesia or Puncture [see Warnings and Precautions (5.3) ] • Most common adverse reactions (>1%) in adult patients are related to bleeding. (6.1) • The most common adverse reactions (≥10%) in pediatric patients were headache, vomiting, and excessive menstrual bleeding. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Apixaban (FDA label)

ELIQUIS is contraindicated in patients with the following conditions: • Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] • Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] • Active pathological bleeding (4) • Severe hypersensitivity to ELIQUIS (4)

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Apixaban (FDA label)

• ELIQUIS can cause serious, potentially fatal, bleeding. Promptly evaluate signs and symptoms of blood loss. An agent to reverse the anti-factor Xa activity of apixaban is available. (5.2) • Prosthetic heart valves: ELIQUIS use not recommended. (5.4) • Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: ELIQUIS use not recommended. (5.6) 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients.

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Apixaban (FDA label)

• Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadministration. ( 2.6 , 7.1 , 12.3) • Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (7.2 , 12.3) 7.1 Combined P-gp and Strong CYP3A4 Inhibitors For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . Concomitant administration of combined P-gp and strong CYP3A4 inhibitors has not been studied in pediatric patients.

Source: FDA prescribing information (DailyMed). Set ID: a454cd24-0c6d-46e8-b1e4-197388606175. SPL document ID: 35ab1342-e927-4bd0-9020-628b859dfb38. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.